D.A. Davidson & Co’s Genmab GMAB Stock Holding History

D.A. Davidson & Co’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,710	Closed	-$253K	–	1386
2023 Q1	$253K	Buy	6,710 +1,103	+20%	+$42.4K	﹤0.01%	1142
2022 Q4	$238K	Buy	+5,607	New	+$231K	﹤0.01%	1131

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.A. Davidson & Co's GMAB Position: Q2 2023 in Review

D.A. Davidson & Co sold out of Genmab (GMAB) in Q2 2023, closing a stake of 6,710 shares — an estimated $253K sold.

D.A. Davidson & Co first reported a position in GMAB in Q4 2022 and held it in 2 quarters. The position peaked at $253K in Q1 2023. 213 funds tracked by Wall St. Rank hold GMAB as of Q2 2023.

D.A. Davidson & Co reported no remaining Genmab position as of Q2 2023 after selling out during the quarter.
D.A. Davidson & Co sold 6,710 Genmab shares in Q2 2023, an estimated $253K.
D.A. Davidson & Co first reported a position in Genmab in Q4 2022 and held it in 2 quarters.
D.A. Davidson & Co's Genmab position peaked at $253K in Q1 2023.
213 funds tracked by Wall St. Rank held Genmab as of Q2 2023.

Based on D.A. Davidson & Co's 13F filing for Q2 2023, filed 11 Aug 2023.